Mo Mandegar

Mo Mandegar, D.Phil., is a seasoned professional in the field of gene and cell therapies, currently serving as VP and Site Head of Discovery Biology at Ascend Gene & Cell Therapies since January 2022, where responsibilities include building next-generation therapy platforms. Mo co-founded GlacierBio in September 2021 and previously held key roles at Tenaya Therapeutics, leading the discovery of HDAC6 inhibitors for cardioprotective targets and co-inventing the first-in-class small molecule TN-301, now in Phase I clinical trials. Prior experience includes postdoctoral fellowships at Gladstone Institutes, and a D.Phil. from the University of Oxford, where research focused on gene therapy and the development of novel vector systems. Mo has contributed to multiple significant publications throughout a distinguished career, underscoring a strong commitment to advancing therapeutic science.